Kate Foreman specializes in the economics of antitrust, with a focus on life sciences and big tech. Dr. Foreman’s expertise spans multiple industries, including agricultural products, real estate, pharmaceuticals, electronics, consumer financial products, cloud services, SaaS, medical services, dental products, and construction products.
Dr. Foreman’s experience includes assessing potential liability and damages in cases involving alleged price-fixing, output restrictions, exclusionary contracts, and other anticompetitive behavior. She also has experience evaluating market definition, analyzing bid data, and estimating price effects in the context of proposed mergers and acquisitions, including in zero-price and two-sided platforms. Dr. Foreman has guided numerous firms through complex data submissions in connection with Second Requests and other requests for information from the Agencies, and she has assisted in Agency engagement throughout the transaction process.
In the area of life sciences, Dr. Foreman’s experience spans small molecule and biologics in a range of matters, including those involving price-fixing, reverse payment settlements, reasonable royalties, pharmaceutical and health care mergers, rebating practices, assessment of commercial success, and contract disputes.
Prior to joining NERA, Dr. Foreman was a graduate student instructor and researcher at the University of California, Berkeley, and a consultant at the National Academy of Sciences. Dr. Foreman has taught courses in microeconomics, macroeconomics, statistics, game theory, energy, and organizational behavior in the United States, Canada, and China.